For example, histone deacetylase (HDAC) inhibitors, compounds shown to promote the expression of a number of genes including SMN2 have already been entered into clinical trials for SMA [47 and references therein]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.